TheEdgeResearch
Home / Stocks / VTIAF

FamiCord AG (VTIAF)

OTC Healthcare Biotechnology
$3.10 ▲ +0.00%
Market Cap
$54.0M
Sector
Healthcare
Industry
Biotechnology
Beta
0.60
52-Wk Range
3.1-6.38
CEO
Jakub Julian Baran
Country
DE
Currency
USD

FamiCord AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Leipzig, SX, DE. The stock last traded at $3.10, up 0.00% on the session, giving a market capitalisation of $54.0M. On trailing twelve-month figures it carries a trailing P/E of -5.25, a net margin of -8.7%. Its beta of 0.60 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-5.25
Price / Sales
0.46
Price / Book
7.87
EV / EBITDA
9.04
Gross margin
61.7%
Operating margin
-3.1%
Net margin
-8.7%
Return on equity
—
Debt / equity
4.56
Current ratio
0.69
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
742
IPO date
2014-10-06
Headquarters
Leipzig, SX, DE
About FamiCord AG

FamiCord AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, FamiCord manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, FamiCord is headquartered in Leipzig, Germany.

Comparable companies

FamiCord AG is most often compared with the following Healthcare names:

HLTRFHOFBFJUSHFKNTPFLDXHFPOLBFRCELSNZZFTOKIFVMTHF
More research on VTIAF
VTIAF technical analysis VTIAF TheEdge Score Compare against peers
Open full interactive analysis & DCF →